BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:MedImmune LLC readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies MedImmune LLC's drugs run\, from 
 ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07081633-2015@assetmemo.bio
DTSTAMP:20261121T005006Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Tremelimumab: Phase 2 readout est. (NCT07081633)
DESCRIPTION:Tremelimumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Durv
 alumab and Tremelimumab With Lenvatinib as First-line Treatment in Patient
 s With Unresectable Hepatocellular Carcinoma\nEstimated primary completion
 : 30 November 2026. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/t
 remelimumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07081633
URL:https://assetmemo.bio/drug/tremelimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05692180-1322@assetmemo.bio
DTSTAMP:20261121T005006Z
DTSTART;VALUE=DATE:20261223
DTEND;VALUE=DATE:20261224
SUMMARY:Fasenra (Benralizumab): Phase 3 readout est. (NCT05692180)
DESCRIPTION:Fasenra (Benralizumab)\, phase 3\, Asthma.\nStudy: A Multicentr
 e\, Randomised\, Double-blind\, Parallel Group\, Placebo-controlled\, Time
 -to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benra
 lizumab in Paediatric Patients With Severe Eosinophilic Asthma\nEstimated 
 primary completion: 23 December 2026. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/benralizumab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT05692180
URL:https://assetmemo.bio/drug/benralizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05925803-5367@assetmemo.bio
DTSTAMP:20261121T005006Z
DTSTART;VALUE=DATE:20270106
DTEND;VALUE=DATE:20270107
SUMMARY:Anifrolumab: Phase 3 readout est. (NCT05925803)
DESCRIPTION:Anifrolumab\, phase 3\, Systemic Sclerosis.\nStudy: Determine E
 ffectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)\nEstimated prima
 ry completion: 6 January 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/anifrolumab#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT05925803
URL:https://assetmemo.bio/drug/anifrolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05138133-5367@assetmemo.bio
DTSTAMP:20261121T005006Z
DTSTART;VALUE=DATE:20270223
DTEND;VALUE=DATE:20270224
SUMMARY:Anifrolumab: Phase 3 readout est. (NCT05138133)
DESCRIPTION:Anifrolumab\, phase 3\, Systemic Lupus Erythematosus.\nStudy: P
 hase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lu
 pus Nephritis\nEstimated primary completion: 23 February 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/anifrolumab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT05138133
URL:https://assetmemo.bio/drug/anifrolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06455449-5367@assetmemo.bio
DTSTAMP:20261121T005006Z
DTSTART;VALUE=DATE:20280110
DTEND;VALUE=DATE:20280111
SUMMARY:Anifrolumab: Phase 3 readout est. (NCT06455449)
DESCRIPTION:Anifrolumab\, phase 3\, Idiopathic Inflammatory Myopathies.\nSt
 udy: A Study to Investigate the Efficacy and Safety of Anifrolumab Adminis
 tered as Subcutaneous Injection and Added to Standard of Care Compared Wit
 h Placebo Added to Standard of Care in Adult Participants With Idiopathic 
 Inflammatory Myopathies (Polymyositis and Dermatomyositis)\nEstimated prim
 ary completion: 10 January 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/anifrolumab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06455449
URL:https://assetmemo.bio/drug/anifrolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06512883-1322@assetmemo.bio
DTSTAMP:20261121T005006Z
DTSTART;VALUE=DATE:20280220
DTEND;VALUE=DATE:20280221
SUMMARY:Fasenra (Benralizumab): Phase 3 readout est. (NCT06512883)
DESCRIPTION:Fasenra (Benralizumab)\, phase 3.\nStudy: A Trial to Investigat
 e Benralizumab in Children With Eosinophilic Diseases\nEstimated primary c
 ompletion: 20 February 2028. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/benralizumab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06512883
URL:https://assetmemo.bio/drug/benralizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07751848-5367@assetmemo.bio
DTSTAMP:20261121T005006Z
DTSTART;VALUE=DATE:20280825
DTEND;VALUE=DATE:20280826
SUMMARY:Anifrolumab: Phase 3 readout est. (NCT07751848)
DESCRIPTION:Anifrolumab\, phase 3\, Systemic Lupus Erythematosus.\nStudy: A
  Study of Outcomes in Chinese Patients Treated With Anifrolumab Who Have A
 ctive Mod-severe Systemic Lupus Erythematosus\nEstimated primary completio
 n: 25 August 2028. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/an
 ifrolumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07751848
URL:https://assetmemo.bio/drug/anifrolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05835310-5367@assetmemo.bio
DTSTAMP:20261121T005006Z
DTSTART;VALUE=DATE:20281005
DTEND;VALUE=DATE:20281006
SUMMARY:Anifrolumab: Phase 3 readout est. (NCT05835310)
DESCRIPTION:Anifrolumab\, phase 3\, Systemic Lupus Erythematosus.\nStudy: A
 n Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic L
 upus Erythematosus in Pediatric Participants\nEstimated primary completion
 : 5 October 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ani
 frolumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT05835310
URL:https://assetmemo.bio/drug/anifrolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07430306-5367@assetmemo.bio
DTSTAMP:20261121T005006Z
DTSTART;VALUE=DATE:20290126
DTEND;VALUE=DATE:20290127
SUMMARY:Anifrolumab: Phase 3 readout est. (NCT07430306)
DESCRIPTION:Anifrolumab\, phase 3\, Systemic Lupus Erythematosus.\nStudy: A
  Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in I
 mmunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus\n
 Estimated primary completion: 26 January 2029. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/anifrolumab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07430306
URL:https://assetmemo.bio/drug/anifrolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07444567-1322@assetmemo.bio
DTSTAMP:20261121T005006Z
DTSTART;VALUE=DATE:20291227
DTEND;VALUE=DATE:20291228
SUMMARY:Fasenra (Benralizumab): Phase 3 readout est. (NCT07444567)
DESCRIPTION:Fasenra (Benralizumab)\, phase 3\, Asthma.\nStudy: Roll-over St
 udy for Participants Who Have Completed a Previous Clinical Study With Ben
 ralizumab (Fasenra) and Benefit From Continued Treatment\nEstimated primar
 y completion: 27 December 2029. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/benralizumab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07444567
URL:https://assetmemo.bio/drug/benralizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06921785-2015@assetmemo.bio
DTSTAMP:20261121T005006Z
DTSTART;VALUE=DATE:20300315
DTEND;VALUE=DATE:20300316
SUMMARY:Tremelimumab: Phase 3 readout est. (NCT06921785)
DESCRIPTION:Tremelimumab\, phase 3\, Hepatocellular Carcinoma.\nStudy: Phas
 e III Study of Rilvegostomig in Combination With Bevacizumab With or Witho
 ut Tremelimumab as First-line Treatment of Hepatocellular Carcinoma\nEstim
 ated primary completion: 15 March 2030. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/tremelimumab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06921785
URL:https://assetmemo.bio/drug/tremelimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07630714-5367@assetmemo.bio
DTSTAMP:20261121T005006Z
DTSTART;VALUE=DATE:20300902
DTEND;VALUE=DATE:20300903
SUMMARY:Anifrolumab: Phase 2 readout est. (NCT07630714)
DESCRIPTION:Anifrolumab\, phase 2\, Systemic Lupus Erythematosus.\nStudy: A
  Study to Investigate Pharmacokinetics\, Pharmacodynamics\, and Safety of 
 Subcutaneous Anifrolumab in Pediatric Participants 5 to < 18 Years of Age 
 With Systemic Lupus Erythematosus\nEstimated primary completion: 2 Septemb
 er 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/anifrolumab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0763
 0714
URL:https://assetmemo.bio/drug/anifrolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07691970-5367@assetmemo.bio
DTSTAMP:20261121T005006Z
DTSTART;VALUE=DATE:20321230
DTEND;VALUE=DATE:20321231
SUMMARY:Anifrolumab: Phase 3 readout est. (NCT07691970)
DESCRIPTION:Anifrolumab\, phase 3\, Systemic Lupus Erythematosus.\nStudy: R
 ollover Study for Participants Who Have Completed a Previous Clinical Stud
 y With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Trea
 tment\nEstimated primary completion: 30 December 2032. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/anifrolumab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07691970
URL:https://assetmemo.bio/drug/anifrolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
